Emerald Advisers LLC Acquires New Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Emerald Advisers LLC bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 8,845 shares of the biotechnology company’s stock, valued at approximately $915,000. Other hedge funds and other institutional investors have also recently bought […]

Related Keywords

United States ,America ,Johnc Klock ,Jeffrey Robert Ajer ,Jean Jacques Bienaime ,Sanfordc Bernstein ,Nasdaq ,Acadian Asset Management ,Emerald Advisers ,Altshuler Shaham Ltd ,Ellevest Inc ,Morgan Stanley ,Janiczek Wealth Management ,Credit Suisse Group ,Biomarin Pharmaceutical Inc ,Baystate Wealth Management ,Securities Exchange Commission ,Biomarin Pharmaceutical ,Get Rating ,Shaham Ltd ,Asset Management ,Wealth Management ,Jacques Bienaime ,Exchange Commission ,Robert Ajer ,Suisse Group ,Marin Pharmaceutical ,Visit Holdingschannel ,Biomarin Pharmaceutical Daily ,Nasdaq Bmrn ,Bmrn ,Medical ,09061g10 ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,